NCT00367679 - Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

Non-Small Cell Lung CancerLung Cancer, Non-Small Cell

Interventions

DRUG

Pazopanib

Pazopanib is an oral, potent, multi-target receptor tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit. Subjects were to receive 800 mg oral pazopanib daily for a minimum of 2 weeks to a maximum of 6 weeks.

Trial Locations (12)

10016

GSK Investigational Site, New York

10065

GSK Investigational Site, New York

11355

GSK Investigational Site, Flushing

19718

GSK Investigational Site, Newark

33136

GSK Investigational Site, Miami

60612

GSK Investigational Site, Chicago

80045

GSK Investigational Site, Aurora

91010

GSK Investigational Site, Duarte

91120

GSK Investigational Site, Jerusalem

92270

GSK Investigational Site, Rancho Mirage

07652

GSK Investigational Site, Paramus

08035

GSK Investigational Site, Barcelona